NCT02037373View on ClinicalTrials.gov

Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

TerminatedOBSERVATIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
CoagulopathyEndstage Liver Disease
Interventions
BIOLOGICAL

Octaplas™

Octaplas™ infusion solution for IV administration as prescribed by the treating physician.

BIOLOGICAL

Plasma

Plasma as prescribed by the treating physician.

Trial Locations (4)

15232

Octapharma Research Site, Pittsburgh

19141

Octapharma Research Site, Philadelphia

37232

Octapharma Research Site, Nashville

92354

Octapharma Research Site, Loma Linda

Sponsors

Lead Sponsor

Octapharma
All Listed Sponsors
lead

Octapharma

INDUSTRY